


The background of the slide features a close-up, top-down view of several pills and a stethoscope. The pills are in various colors: white, yellow, and pink/red. Some are oval-shaped, while others are capsule-shaped. A silver stethoscope with a brown leather-like handle is positioned on the right side, with its chest piece resting on a yellow pill. The overall lighting is soft and even.

Bakers Union and FELRA Health and Welfare Fund

Quarterly Review
January – September 2022

December 7, 2022

Today's Topics

1. Key Discussion Topics
2. Performance Summary
3. Trend
4. Top Disease States
5. Rebates
6. Outcomes
 - Clinical Outcomes
 - Vigilant Outcomes
 - VCS Outcomes

Your OptumRx Team

Paul Marcus

VP, Client Management
Labor & Trust

Holly Agoney

Strategic Account Executive
Labor & Trust

Caroline Atwood

Director, Client
Management
Labor & Trust

Autumn Leblanc

Pharmacy Account
Manager
Labor & Trust

Fabian Gonzales

Pharmacy Service
Specialist
Labor & Trust

Current Plan Design

☐ Deductible, Ben Max, MOOP, Copays

Plan 1 (group BFWRX):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$2,850 Individual / \$5,700 Family

Plan 2 (group BFWRX2) & Plan 3 (group BFWRX3):	
Deductible:	This plan has no deductible.
Benefit Maximum:	\$2,000 per year for Growth Hormones medications only
Max out of Pocket:	\$1,850 Individual / \$3,700 Family

Co-pays			
Plan 1 (group BFWRX) & Plan 2 (group BFWRX2):			
	Retail		Mail
*Generic:	\$10	*Generic:	\$20
*Brand:	\$15	*Brand:	\$30
*NP Brand:	\$30	*NP Brand:	\$60
*Specialty:	Run trial claim for co-pay		*Specialty: N/A

☐ Effective 7/1/19

- ☐ Diabetes Program
- ☐ Comprehensive Ums
- ☐ Vigilant Program
- ☐ RxOTC Program

☐ Effective 8/1/2020

- ☐ Orphan Drug Program

☐ Effective 3/1/2021

- ☐ Opioid Mgmt – tighter refill window & UMs

Plan 3 (group BFWRX3):		
	Retail / Mail	
*Generic:	5%	(\$5 min.)
*Brand:	15%	(\$15 min.)
*NP Brand:	25%	(\$25 min.)
*Specialty:	Run trial claim for co-pay	

☐ Effective 7/1/2021

- ☐ Premium Formulary
- ☐ Mandatory Mail (MSS)

☐ Effective 1/1/2022

- ☐ Split-fill/Smart-fill

☐ Effective 3/1/2022

- ☐ CCAA/VCS

Key Discussion Topics

- ❑ Per Member Per Month (PMPM) trend = 8.3% Specialty trend = negative -27.0%
- ❑ Specialty represents 0.9% of claims

- ❑ Top 5 disease states accounted for 74% of total plan paid
 - ❑ Top traditional disease state: Diabetes
 - ❑ Top specialty disease state: Inflammatory Conditions


- ❑ Rebates – Jan – Sept 2022
 - ❑ Estimated - \$126,700

- ❑ Clinical Outcomes savings
 - ❑ **UM (PA, ST, QL)** – Oct 2021 – Sept 2022
 - ❑ Savings = \$77,700
 - ❑ **Vigilant** – Oct 2021 - Sept 2022
 - ❑ Savings = \$16,907
 - ❑ **VCS** – Jan – Spet 2022
 - ❑ Savings = \$5,666

Key Statistics

Key Statistics – Performance Summary

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -51.
- Number of utilizers has decreased by -70.

Total Rx's

CURRENT

5,888

PREVIOUS

6,561

PERCENT CHANGE

-10.3%

Total plan paid

CURRENT

\$666,236

PREVIOUS

\$665,699

PERCENT CHANGE

0.1%

Utilizers

CURRENT

437

PREVIOUS

507

PERCENT CHANGE

-13.8%

Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL


Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was 8.3%, compared to the benchmark trend of 11.8%
- Member Paid Share changed by 8.0% period over period, compared to the benchmark of -5.6%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Average age	43.0	42.1	2.1%	36.7	1.0%	36.9	0.0%
Plan paid PMPM	\$118.78	\$109.72	8.3%	\$107.99	11.8%	\$118.83	11.6%
Plan paid per Rx	\$113.15	\$101.46	11.5%	\$146.41	13.6%	\$147.47	11.6%
Rxs PMPM	1.050	1.081	-2.9%	0.738	-1.5%	0.806	0.0%
Average days supply	29.6	27.3	8.2%	39.4	2.1%	39.2	2.1%
Days supply PMPM	31.0	29.6	5.1%	29.0	0.5%	31.6	2.1%
Member paid share	9.2%	8.5%	8.0%	10.4%	-5.6%	11.8%	-2.7%
Member paid per Rx	\$11.42	\$9.41	21.4%	\$17.10	6.5%	\$19.82	8.2%
Generic dispensing rate	82.7%	80.5%	2.8%	86.6%	2.1%	85.4%	1.6%
GDR-without Vaccines	86.2%	88.5%	-2.6%	88.9%	-0.4%	88.1%	-1.1%
Home delivery rate	4.8%	2.3%	110.1%	7.3%	3.3%	5.3%	1.5%
Retail 90 rate	1.4%	3.0%	-51.7%	15.6%	6.2%	19.0%	5.6%
Percent of specialty plan paid	19.6%	29.1%	-32.6%	46.9%	4.4%	51.2%	1.8%

Specialty Key Statistics

Client totals



The key metrics here help highlight the changes Bakers Union and FELRA Health and Welfare Fund has experienced period over period.

- Eligibility has decreased by -51.
- Number of utilizers has increased by 1.

Total Rx's

CURRENT

55

PREVIOUS

44

PERCENT CHANGE

25.0%

Total plan paid

CURRENT

\$130,735

PREVIOUS

\$193,772

PERCENT CHANGE

-32.5%

Utilizers

CURRENT

6

PREVIOUS

5

PERCENT CHANGE

20.0%

Specialty Key Statistics

Key statistics with benchmark comparison

Benchmark comparison 1

LABOR AND TRUST

Benchmark comparison 2

COMMERCIAL

Comparing metrics to benchmarks help showcase areas of focus.

- Client trend was -27.0%, compared to the benchmark trend of 16.8%
- Member Paid Share changed by 1,289.3% period over period, compared to the benchmark of -4.8%

Key statistics	Curr	Prev	Percent change	Curr	Percent change	Curr	Percent change
Plan paid PMPM	\$23.31	\$31.94	-27.0%	\$50.66	16.8%	\$60.80	13.5%
Plan paid per Rx	\$2,377.00	\$4,403.91	-46.0%	\$6,046.03	7.0%	\$6,066.57	5.9%
Rxs PMPM	0.010	0.007	35.2%	0.008	9.2%	0.010	7.2%
Average days supply	29.0	29.1	-0.4%	32.9	2.3%	32.5	1.4%
Days supply PMPM	0.3	0.2	34.7%	0.3	11.7%	0.3	8.7%
Member paid share	4.4%	0.3%	1,289.3%	6.2%	-4.8%	6.1%	9.0%
Member paid per Rx	\$110.20	\$14.09	682.1%	\$402.60	1.5%	\$397.49	16.1%
Generic dispensing rate	49.1%	18.2%	170.0%	22.2%	-4.5%	20.3%	-6.9%
Home delivery rate	1.8%	6.8%	-73.3%	4.8%	-6.8%	3.5%	-5.4%
Retail 90 rate	0.0%	0.0%	0.0%	5.7%	19.0%	6.0%	7.2%

Trend Summary

Trend Summary

Trend

Plan paid PMPM has increased 8.3% over the previous period driven primarily by drug mix in traditional and drug mix for specialty.

Specialty represents 0.9% of claims.



-3.6% under benchmark



+15% over benchmark




-43.8% under benchmark

Traditional vs. Specialty Trend Components

Traditional trend: 22.7%

Benchmark comparison: LABOR AND TRUST


- Traditional trend contributed 195.3% to the overall trend (8.3%)
- Traditional accounts for 80.4% of overall total plan paid and was up from 70.9% in the prior period



Specialty trend: -27.0%

Benchmark comparison: LABOR AND TRUST

- Specialty trend contributed -95.3% to the overall trend (8.3%)
- Specialty accounts for 19.6% of overall total plan paid and was down from 29.1% in the prior period



Top Disease States & Top 20 Drugs

Top Disease States

Top 5 disease states account for 74% of total Plan Paid

- Diabetes accounts for 26.7% of total plan paid, with trend driven by Utilization. VICTOZA was the top drug
- Inflammatory Conditions accounts for 18.6% of total plan paid, with trend driven by Utilization. DUPIXENT was the top drug

Sort by: Plan Paid

Diabetes ▲

PMPM

\$31.69

Trend

16.1%

Top driver:
Utilization

Inflammatory Conditions ▼

PMPM

\$22.03

Trend

-30.8%

Top driver:
Utilization

Asthma / COPD ▲

PMPM

\$13.38

Trend

155.5%

Top driver:
Utilization

HIV ▲

PMPM

\$12.41

Trend

12.2%

Top driver:
Drug Mix

Cardiovascular ▲

PMPM

\$8.01

Trend

16.2%

Top driver:
Drug Mix

All other ▲

PMPM

\$31.27

Trend

14.2%

Top 20 Drugs by Plan Cost

All meds are Brands

Specialty

Rank													Trend components		
Cu	Pv	Bench	Drug name	Therapy class	Utilzr	Rxs	Avg days supply	Total plan paid	Plan paid per Rx	Curr plan paid PMPM	Prev plan paid PMPM	Bench plan paid PMPM	% Trend	Top driver	% Top driver
1	4	6	DUPIXENT	Chronic Inflammatory Disease	2	19	28.0	\$63,679	\$3,351.52	\$11.35	\$5.51	\$2.17	105.9%	Utilzn	105.5%
2	1	1	HUMIRA PEN	Chronic Inflammatory Disease	1	9	28.0	\$55,970	\$6,218.84	\$9.98	\$10.17	\$7.62	-1.9%	Cost	6.5%
3	5	217	STRIBILD	HIV-Multiclass Combo	1	8	30.0	\$29,385	\$3,673.10	\$5.24	\$4.58	\$0.07	14.4%	Utilzn	8.2%
4	6	10	BIKTARVY	HIV-Multiclass Combo	1	7	30.0	\$23,057	\$3,293.87	\$4.11	\$3.59	\$1.66	14.6%	Utilzn	8.2%
5	19	32	SYMBICORT	Inhaled Asthma/COPD Combo	6	56	33.8	\$20,229	\$361.24	\$3.61	\$1.22	\$0.60	195.8%	Utilzn	209.7%
6	7	33	VICTOZA	GLP-1 Receptor Agonists	2	16	37.5	\$20,173	\$1,260.80	\$3.60	\$2.74	\$0.59	31.4%	Utilzn	27.3%
7	14	4	TRULICITY	GLP-1 Receptor Agonists	4	23	28.0	\$18,654	\$811.05	\$3.33	\$1.61	\$3.18	106.4%	Utilzn	107.3%
8	11	5	JARDIANCE	SGLT-2 Inhibitors & Combos	6	34	30.0	\$17,455	\$513.38	\$3.11	\$2.07	\$2.80	50.6%	Utilzn	67.2%
9	77	37	ADVAIR DISKUS	Inhaled Asthma/COPD Combo	4	43	30.0	\$16,816	\$391.08	\$3.00	\$0.24	\$0.50	1,166.5%	Utilzn	1,450.4%
10	9	175	PREZCOBIX	HIV-Multiclass Combo	1	5	42.0	\$14,809	\$2,961.74	\$2.64	\$2.34	\$0.09	13.0%	Utilzn	8.2%
11	12	21	JANUMET	DPP-4 Inhibitors & Combos	3	22	38.2	\$13,592	\$617.80	\$2.42	\$1.71	\$0.83	41.6%	Utilzn	37.7%
12	17	30	ENTRESTO	Angiotensin II Receptor & Nephrylsin Inhibitor (ARNI)	2	14	38.6	\$10,569	\$754.90	\$1.88	\$1.37	\$0.63	37.4%	Utilzn	29.8%
13	22	14	LANTUS SOLOSTAR	Insulin	10	23	37.6	\$9,997	\$434.67	\$1.78	\$0.99	\$1.38	79.8%	Utilzn	91.1%
14	10	128	LANTUS	Insulin	5	14	29.5	\$9,352	\$667.97	\$1.67	\$2.28	\$0.15	-27.0%	Cost	-28.4%
15	44	47	BREO ELLIPTA	Inhaled Asthma/COPD Combo	2	26	30.0	\$9,103	\$350.13	\$1.62	\$0.46	\$0.40	255.4%	Utilzn	251.5%
16	8	9	JANUVIA	DPP-4 Inhibitors & Combos	3	18	30.0	\$8,945	\$496.96	\$1.59	\$2.37	\$1.71	-32.8%	Utilzn	-36.3%
17	18	100	DEXILANT	Proton Pump Inhibitors	3	28	30.0	\$8,060	\$287.84	\$1.44	\$1.28	\$0.20	12.0%	Utilzn	12.2%
18	-	62	CREON	Digestive Enzymes	1	4	30.0	\$7,929	\$1,982.32	\$1.41	\$0.00	\$0.30	-	-	-
19	20	94	BYDUREON BCISE	GLP-1 Receptor Agonists	1	10	28.6	\$7,492	\$749.22	\$1.34	\$1.20	\$0.21	11.2%	Utilzn	10.5%
20	28	8	ELIQUIS	Oral Anticoagulants	5	15	29.9	\$7,320	\$488.02	\$1.31	\$0.70	\$1.88	85.1%	Utilzn	79.5%
Total					45	394	31.9	\$372,586	\$945.65	\$66.43	\$46.43	\$26.93	43.1%		66.4%
Plan Total					437	5,888	29.6	\$666,236	\$113.15	\$118.78	\$109.72	\$107.99	8.3%		5.1%

Rebates


Rebate Performance Summary

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Sep 2022

Benchmark: LABOR AND TRUST

Current rebate value: \$22.60 PMPM



Rebate impact on Plan Paid PMPM

Managing drug spend to a lowest net cost PMPM is achieved through adoption of high performing formulary strategies and driving to lowest net cost products when clinically appropriate. Bakers Union and FELRA Health and Welfare Fund's members adherence to the formulary has earned an offset on PMPM costs, yielding a net plan paid PMPM of \$96.18, versus plan paid PMPM of \$118.78.

Net financial PMPM performance

	Drug cost	Member Paid	Plan Paid	Rebates	Net plan paid
Traditional	\$106.37	\$10.91	\$95.47	\$18.42	\$77.05
Specialty	\$24.39	\$1.08	\$23.31	\$4.18	\$19.13
Total	\$130.76	\$11.99	\$118.78	\$22.60	\$96.18

Total estimated rebate yield for reporting period: \$126.7K

Rebate Performance by Disease State

Disease	Drug cost PMPM	Member paid PMPM	Plan paid PMPM	Rebates PMPM	Net plan paid PMPM	Rebate offset
Diabetes	\$33.58	\$1.89	\$31.69	\$8.55	\$23.13	27.0%
Inflammatory Conditions	\$23.09	\$1.06	\$22.03	\$4.18	\$17.85	19.0%
Asthma / COPD	\$14.09	\$0.72	\$13.38	\$2.97	\$10.41	22.2%
Diabetic Supplies	\$2.01	\$0.20	\$1.81	\$1.58	\$0.23	87.2%
Cardiovascular	\$9.97	\$1.96	\$8.01	\$1.09	\$6.92	13.6%
Ulcer/Acid Reflux/Gerd	\$1.95	\$0.19	\$1.76	\$0.78	\$0.98	44.4%
HIV	\$12.81	\$0.41	\$12.41	\$0.56	\$11.85	4.5%
Blood Clot Prevention/Stroke Prevention	\$2.21	\$0.16	\$2.05	\$0.52	\$1.53	25.3%
Gastrointestinal, Misc	\$1.75	\$0.08	\$1.67	\$0.42	\$1.24	25.5%
Cholesterol Lowering Agents	\$4.83	\$1.10	\$3.73	\$0.32	\$3.41	8.6%
Male And Female Hormone Replacement	\$0.78	\$0.07	\$0.71	\$0.22	\$0.49	31.5%
Ophthalmic Agents	\$1.31	\$0.09	\$1.22	\$0.22	\$1.00	18.1%
Overactive Bladder / Incontinence	\$0.91	\$0.04	\$0.87	\$0.17	\$0.70	19.7%
Contraception	\$1.47	\$0.03	\$1.44	\$0.17	\$1.27	11.6%
Glaucoma	\$1.15	\$0.05	\$1.10	\$0.14	\$0.96	12.8%
Antibiotics	\$0.82	\$0.29	\$0.52	\$0.14	\$0.39	26.5%
Antipsychotics	\$1.28	\$0.30	\$0.98	\$0.11	\$0.87	11.6%
Anti-Inflammatory (Steroids)	\$0.15	\$0.07	\$0.08	\$0.11	-\$0.03	132.4%
Severe Allergic Reaction	\$0.09	\$0.00	\$0.09	\$0.06	\$0.03	64.7%
Ear Condition	\$0.34	\$0.03	\$0.31	\$0.06	\$0.25	18.6%
Misc Skin Condition	\$1.61	\$0.17	\$1.45	\$0.06	\$1.39	3.9%
Migraine/Pain Relief	\$0.34	\$0.05	\$0.29	\$0.06	\$0.23	19.2%
Narcotic Analgesics	\$0.24	\$0.11	\$0.13	\$0.05	\$0.07	42.7%
Topical Anti-Fungal	\$0.31	\$0.08	\$0.24	\$0.03	\$0.21	12.1%
Seizure Disorders	\$1.54	\$0.27	\$1.27	\$0.03	\$1.24	2.3%

Clinical Outcomes

UM Outcomes


Utilization management savings: \$10.37 PMPM

Your program savings: **\$77.7K**

Ensuring patients meet appropriate clinical criteria when initiating medication therapy not only helps to ensure that the patient is being treated safely according to guidelines, but also drives significant savings for both Bakers Union and FELRA Health and Welfare Fund and for members. Bakers Union and FELRA Health and Welfare Fund has realized over \$77.7K in savings. Based on a study by OptumRx, leveraging UM strategies that drive members to appropriate and often lower cost medications for treatment can save a member up to \$620 annually in out of pocket copayments.

[Review program description](#)

Outcomes date range: Jul 2021 - Jun 2022



Prior authorization

PMPM SAVINGS

\$4.18

NUMBER OF MEMBERS IMPACTED

35

NUMBER OF INTERVENTIONS

43

Quantity limits

PMPM SAVINGS

\$4.02

NUMBER OF MEMBERS IMPACTED

8

NUMBER OF INTERVENTIONS

9

Step therapy

PMPM SAVINGS

\$2.17

NUMBER OF MEMBERS IMPACTED

78

NUMBER OF INTERVENTIONS

96

QL savings is based only on Maximum Daily Dose edits.

Vigilant Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: **Oct 2021 - Sep 2022**

Total program savings: \$2.26 PMPM

[View outcomes dashboard](#)

Vigilant Drug Outcomes – Cost Avoidance

By leveraging the Vigilant Drug Program, Bakers Union and FELRA Health and Welfare Fund has:

- Avoided \$16.9K in pharmacy spend
- Switched 11 claims to lower cost alternatives
- 12 claims were abandoned



TOTAL PLAN PAID SAVINGS

\$16,907

TOTAL PROGRAM SAVINGS

1.9%

TOTAL MEMBERS IMPACTED

23

Savings by Vigilant Drug List

Sort by: Members impacted Plan paid PMPM savings

Vigilant drug list	PMPM savings	Members impacted	Interventions
High Cost Generics	\$0.40	8	8
Clinical Duplicates	\$0.71	5	5
High Cost Brands with Generics	\$0.47	4	4
Non-FDA Approved Drugs	\$0.06	3	3
New Drugs to Market	\$0.58	2	2
Creams & Patches	\$0.03	1	1

VCS Copay Solutions Outcomes

Bakers Union and FELRA Health and Welfare Fund

Outcomes date range: Jan - Sep 2022

Total program savings: \$1.01 PMPM

[View outcomes dashboard](#)

Variable copay program savings outcomes

With the OptumRx Variable Copay program, Bakers Union and FELRA Health and Welfare Fund has realized:

- \$5,666 in Plan Paid savings
- \$629.56 average Plan Paid per impacted prescription
- 2 total impacted utilizers
- 9 prescriptions processed through the program out of a possible 29 eligible prescriptions

PLAN PAID SAVINGS

\$5,666

PLAN PAID SAVINGS PER IMPACTED RX

\$629.56

Top 5 drugs based on: Plan paid savings Impacted Rx's

HUMIRA PEN

IMPACTED RXS

7

IMPACTED UTILIZERS

1

PLAN PAID SAVINGS

\$3,500

DUPIXENT

IMPACTED RXS

2

IMPACTED UTILIZERS

1

PLAN PAID SAVINGS

\$2,166


Appendix

Trend Components

Total trend: 8.3%

Benchmark comparison: LABOR AND TRUST

- Bakers Union and FELRA Health and Welfare Fund's overall trend of 8.3% was -3.6% lower than benchmark
- Traditional spend influenced the trend contributing 195.3% (159.1% higher than benchmark)
- Specialty trend contributed -95.3% (159.1% lower than benchmark)



Top 20 traditional

All meds are Brands

Rank													Trend components			
Cu↕	Pv↕	Bench↕	Drug name ↕	Therapy class ↕	Utilzr↕	Rxs↕	Avg days supply↕	Total plan paid↕	Plan paid per Rx↕	Curr plan paid PMPM↕	Prev plan paid PMPM↕	Bench plan paid PMPM↕	% Trend↕	Top driver ↕	% Top driver ↕	
1	1	113	STRIBILD	HIV-Multiclass Combo	1	8	30.0	\$29,385	\$3,673.10	\$5.24	\$4.58	\$0.07	14.4%	Utilzn	8.2%	
2	2	6	BIKTARVY	HIV-Multiclass Combo	1	7	30.0	\$23,057	\$3,293.87	\$4.11	\$3.59	\$1.66	14.6%	Utilzn	8.2%	
3	15	16	SYMBICORT	Inhaled Asthma/COPD Combo	6	56	33.8	\$20,229	\$361.24	\$3.61	\$1.22	\$0.60	195.8%	Utilzn	209.7%	
4	3	17	VICTOZA	★ GLP-1 Receptor Agonists	2	16	37.5	\$20,173	\$1,260.80	\$3.60	\$2.74	\$0.59	31.4%	Utilzn	27.3%	
5	10	2	TRULICITY	★ GLP-1 Receptor Agonists	4	23	28.0	\$18,654	\$811.05	\$3.33	\$1.61	\$3.18	106.4%	Utilzn	107.3%	
6	7	3	JARDIANCE	★ SGLT-2 Inhibitors & Combos	6	34	30.0	\$17,455	\$513.38	\$3.11	\$2.07	\$2.80	50.6%	Utilzn	67.2%	
7	72	19	ADVAIR DISKUS	Inhaled Asthma/COPD Combo	4	43	30.0	\$16,816	\$391.08	\$3.00	\$0.24	\$0.50	1,166.5%	Utilzn	1,450.4%	
8	5	94	PREZCOBIX	HIV-Multiclass Combo	1	5	42.0	\$14,809	\$2,961.74	\$2.64	\$2.34	\$0.09	13.0%	Utilzn	8.2%	
9	8	11	JANUMET	★ DPP-4 Inhibitors & Combos	3	22	38.2	\$13,592	\$617.80	\$2.42	\$1.71	\$0.83	41.6%	Utilzn	37.7%	
10	13	15	ENTRESTO	Angiotensin II Receptor & Neprilysin Inhibitor (ARNI)	2	14	38.6	\$10,569	\$754.90	\$1.88	\$1.37	\$0.63	37.4%	Utilzn	29.8%	
11	18	8	LANTUS SOLOSTAR	Insulin ★	10	23	37.6	\$9,997	\$434.67	\$1.78	\$0.99	\$1.38	79.8%	Utilzn	91.1%	
12	6	75	LANTUS	★ Insulin	5	14	29.5	\$9,352	\$667.97	\$1.67	\$2.28	\$0.15	-27.0%	Cost	-28.4%	
13	40	23	BREO ELLIPTA	Inhaled Asthma/COPD Combo	2	26	30.0	\$9,103	\$350.13	\$1.62	\$0.46	\$0.40	255.4%	Utilzn	251.5%	
14	4	5	JANUVIA	★ DPP-4 Inhibitors & Combos	3	18	30.0	\$8,945	\$496.96	\$1.59	\$2.37	\$1.71	-32.8%	Utilzn	-36.3%	
15	14	57	DEXILANT	Proton Pump Inhibitors	3	28	30.0	\$8,060	\$287.84	\$1.44	\$1.28	\$0.20	12.0%	Utilzn	12.2%	
16	-	31	CREON	Digestive Enzymes	1	4	30.0	\$7,929	\$1,982.32	\$1.41	\$0.00	\$0.30	-	-	-	
17	16	52	BYDUREON BCISE	★ GLP-1 Receptor Agonists	1	10	28.6	\$7,492	\$749.22	\$1.34	\$1.20	\$0.21	11.2%	Utilzn	10.5%	
18	24	4	ELIQUIS	Oral Anticoagulants	5	15	29.9	\$7,320	\$488.02	\$1.31	\$0.70	\$1.86	85.1%	Utilzn	79.5%	
19	9	1	OZEMPIC	★ GLP-1 Receptor Agonists	2	3	84.0	\$7,228	\$2,409.39	\$1.29	\$1.70	\$3.62	-24.0%	Utilzn	-27.9%	
20	11	764	HUMALOG MIX 50/50 KWIKPEN	★ Insulin	1	3	90.0	\$7,162	\$2,387.35	\$1.28	\$1.54	\$0.01	-16.9%	Utilzn	-10.4%	
Total						44	372	33.1	\$267,328	\$718.62	\$47.66	\$33.98	\$20.76	40.3%		60.1%
Plan Total						437	5,833	29.6	\$535,501	\$91.81	\$95.47	\$77.79	\$57.33	22.7%		11.3%

Top 20 specialty

B = Brands
G = Generics

Rank														Trend components		
Cu ↕	Pv ↕	Bench ↕	Drug name ↕	Therapy class ↕	Utilizr ↕	Rxs ↕	Avg days supply ↕	Total plan paid ↕	Plan paid per Rx ↕	Curr plan paid PMPM ↕	Prev plan paid PMPM ↕	Bench plan paid PMPM ↕	% Trend ↕	Top driver ↕	% Top driver ↕	
1	4	3	DUPIXENT	B Chronic Inflammatory Disease	2	19	28.0	\$63,679	\$3,351.52	\$11.35	\$5.51	\$2.17	105.9%	Utilzn	105.5%	
2	1	1	HUMIRA PEN	B Chronic Inflammatory Disease	1	9	28.0	\$55,970	\$6,218.84	\$9.98	\$10.17	\$7.62	-1.9%	Cost	6.5%	
3	5	157	MYCOPHENOLATE MOFETIL	G Transplant	1	9	30.0	\$4,415	\$490.52	\$0.79	\$0.40	\$0.05	97.2%	Cost	73.3%	
4	3	9	OTEZLA	B Chronic Inflammatory Disease	2	0	0.0	\$3,941	\$0.00	\$0.70	\$7.79	\$1.11	-91.0%	Utilzn	-100.0%	
5	-	151	TACROLIMUS	G Transplant	1	18	30.0	\$2,731	\$151.73	\$0.49	\$0.00	\$0.05	-	-	-	
Total						6	55	29.0	\$130,735	\$2,377.00	\$23.31	\$31.94	\$12.42	-27.0%		-47.0%
Plan Total						6	55	29.0	\$130,735	\$2,377.00	\$23.31	\$31.94	\$50.66	-27.0%		-47.0%